Non-Insulin Therapies For Diabetes Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends
Discover trends, market shifts, and competitive outlooks for the non-insulin therapies for diabetes industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has The Non-Insulin Therapies For Diabetes Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market for non-insulin diabetes therapies has seen robust growth in recent times. The market is projected to expand from $19.98 billion in 2024 to $21.41 billion in 2025, marking a compound annual growth rate (CAGR) of 7.1%. The historical growth can be accredited to factors such as greater prevalence of diabetes, increased consciousness about diabetes control, a rise in healthcare spending, lifestyle changes triggering higher instances of the disease, a spike in diagnoses, enhanced government efforts towards diabetes management, and heightened investment in pharmaceutical research and development.
Predictions indicate a robust expansion in the market size for non-insulin diabetes therapies in the coming years, reaching $27.9 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in this timeframe is due to a variety of factors, including a rise in the incidence of diabetes, an increase in awareness about managing the condition, a trend towards combination therapies, an aging population, escalating healthcare costs, the growing utilization of telemedicine, and a preference for oral medication. Significant trends predicted during this forecast period include forward strides in both oral and injectable medications, improvements in drug delivery systems, advances in oral peptide delivery, the embracing of telemedicine and digital health solutions, and advances in combination therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
Which Factors and External Forces Are Driving Demand in the Non-Insulin Therapies For Diabetes Market?
The heightened occurrence rate of diabetes is anticipated to spur the development of non-insulin treatments in the diabetes market. Diabetes is a long-term health condition marked by elevated blood glucose levels which occurs when the body is either incapable of producing sufficient insulin or properly utilizing the insulin it generates. Various factors, such as sedentary lifestyles, unhealthy dietary habits, genetic predisposition, aging demographics, obesity, ethnicity, lack of awareness, restricted healthcare accessibility, and environmental influences, contribute to the increasing cases of diabetes. Non-insulin diabetes treatments work by enhancing insulin sensitivity, decreasing the liver’s glucose production, elevating muscle cells’ glucose absorption, and improving overall glycemic control. For example, a report issued in April 2023 by The British Diabetic Association, a diabetes charity in the UK, indicates that 4.3 million individuals were diagnosed with diabetes in the UK. Compared to the registration data for 2020-21, the number of cases in 2021-22 increased by 148,951. Moreover, more than 2.4 million individuals in the UK are at a high risk of developing type 2 diabetes. Thus, the surge in the occurrence of diabetes is catalyzing the growth of non-insulin treatments in the diabetes market.
Which Primary Segments of the Non-Insulin Therapies For Diabetes Market Are Driving Growth and Industry Transformations?
The non-insulin therapies for diabetes market covered in this report is segmented –
1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp
What Are the Fastest-Growing Geographies in the Non-Insulin Therapies For Diabetes Market?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive the Non-Insulin Therapies For Diabetes Market’s Growth?
Leading businesses in the non-insulin diabetes treatment market are innovating personalized diabetes management systems to improve patient outcomes with real-time monitoring, data analysis, and individualized treatment plans. These tailored diabetes management systems adjust treatment and oversight according to each patient’s specific requirements, employing real-time data and analysis to boost care and results. For example, Eli Lilly and Company, a pharmaceutical firm based in the United States, unveiled the Tempo personalized diabetes management platform in November 2022. The Tempo platform is comprised of three essential components: the Tempo Smart Button, the TempoSmart application, and the prefilled insulin pen named Tempo Pen. These components work in tandem to offer tailored advice to adults suffering from diabetes. This technology is developed to aid adults with type 1 or type 2 diabetes along with their healthcare professionals in making data-driven, informed treatment choices using Lilly insulins.
View the full report here:
What Parameters Are Used to Define the Non-Insulin Therapies For Diabetes Market?
Non-insulin therapies for diabetes refer to medications and treatments used to manage blood sugar levels in diabetic patients without the use of insulin injections. They are essential for regulating blood sugar levels in patients, who either do not need or prefer insulin injections.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16494
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
